49 related articles for article (PubMed ID: 20861098)
1. Commissioning for rare diseases: view from the frontline.
Burls A; Austin D; Moore D
BMJ; 2005 Oct; 331(7523):1019-21. PubMed ID: 16254306
[TBL] [Abstract][Full Text] [Related]
2. Trends in rare disease drug development.
Chen R; Liu S; Han J; Zhou S; Liu Y; Chen X; Zhang S
Nat Rev Drug Discov; 2024 Mar; 23(3):168-169. PubMed ID: 37932437
[No Abstract] [Full Text] [Related]
3. Pharmaceutical policy and innovation for rare diseases: A narrative review.
Alonso Ruiz A; Large K; Moon S; Vieira M
F1000Res; 2023; 12():211. PubMed ID: 38778810
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan.
Alewaidat H; Bataineh Z; Bani-Ahmad M; Alali M; Almakhadmeh A
F1000Res; 2023; 12():741. PubMed ID: 37822316
[TBL] [Abstract][Full Text] [Related]
5. Literature Review on Health Emigration in Rare Diseases-A Machine Learning Perspective.
Skweres-Kuchta M; Czerska I; Szaruga E
Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767849
[TBL] [Abstract][Full Text] [Related]
6. How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries.
Blonda A; Denier Y; Huys I; Kawalec P; Simoens S
Front Pharmacol; 2022; 13():902150. PubMed ID: 35928274
[No Abstract] [Full Text] [Related]
7. A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann BM; Eichinger J; Baumgartner MR
Orphanet J Rare Dis; 2021 Jun; 16(1):292. PubMed ID: 34193232
[TBL] [Abstract][Full Text] [Related]
8. How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.
Blonda A; Denier Y; Huys I; Simoens S
Front Pharmacol; 2021; 12():631527. PubMed ID: 34054519
[No Abstract] [Full Text] [Related]
9. Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches.
Nicod E; Whittal A; Drummond M; Facey K
Orphanet J Rare Dis; 2020 Jul; 15(1):189. PubMed ID: 32690107
[TBL] [Abstract][Full Text] [Related]
10. Can India lead the way in neglected diseases innovation?
Thomas Z; Saha GK; Gopakumar KM; Ganguly NK
BMJ; 2019 Jan; 364():k5396. PubMed ID: 30670384
[No Abstract] [Full Text] [Related]
11. Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey.
Richardson J; Iezzi A; Chen G; Maxwell A
Pharmacoecon Open; 2017 Mar; 1(1):13-23. PubMed ID: 29442298
[TBL] [Abstract][Full Text] [Related]
12. Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients.
Messori A
Sci Pharm; 2016 Jan; 84(4):618-624. PubMed ID: 28656940
[TBL] [Abstract][Full Text] [Related]
13. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.
Paulden M; Stafinski T; Menon D; McCabe C
Pharmacoeconomics; 2015 Mar; 33(3):255-69. PubMed ID: 25412735
[TBL] [Abstract][Full Text] [Related]
14. Orphan drugs policies: a suitable case for treatment.
Drummond M; Towse A
Eur J Health Econ; 2014 May; 15(4):335-40. PubMed ID: 24435513
[TBL] [Abstract][Full Text] [Related]
15. Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach.
Fellows GK; Hollis A
Orphanet J Rare Dis; 2013 Nov; 8():180. PubMed ID: 24237605
[TBL] [Abstract][Full Text] [Related]
16. The legal imperative for treating rare disorders.
Hyry HI; Roos JC; Manuel J; Cox TM
Orphanet J Rare Dis; 2013 Sep; 8():135. PubMed ID: 24010951
[TBL] [Abstract][Full Text] [Related]
17. Sustainable rare diseases business and drug access: no time for misconceptions.
Rollet P; Lemoine A; Dunoyer M
Orphanet J Rare Dis; 2013 Jul; 8():109. PubMed ID: 23879976
[TBL] [Abstract][Full Text] [Related]
18. Orphan drugs for rare diseases: is it time to revisit their special market access status?
Simoens S; Cassiman D; Dooms M; Picavet E
Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
[TBL] [Abstract][Full Text] [Related]
19. Is it time to revisit orphan drug policies?
McCabe C; Stafinski T; Menon D
BMJ; 2010 Sep; 341():c4777. PubMed ID: 20861098
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
